Tofacitinib: A paradigm shift in rheumatoid arthritis management

Tofacitinib, a Janus kinase (JAK) inhibitor, represents a significant advancement in the treatment of rheumatoid arthritis (RA), a chronic inflammatory disorder. This manuscript provides an in-depth review of the efficacy, safety, and clinical application of tofacitinib in RA management. Through a comprehensive analysis of clinical trials, real-world studies, and comparative assessments with other RA therapies, we aim to elucidate the role of tofacitinib in improving patient outcomes. The review highlights the mechanisms of action, clinical efficacy, safety profile, and practical considerations for incorporating tofacitinib into RA treatment regimens.